Anti-CD20 monoclonal antibody therapy in multiple myeloma

Research output: Contribution to journalArticle

76 Citations (Scopus)

Abstract

CD20 is a particularly appealing target that is expressed on the surface of almost all B cells, with no significant shedding, secretion or internalization. In contrast to the demonstrated efficacy of anti-CD20 strategies in various B-cell lymphoproliferative disorders, the role of such therapy in multiple myeloma is undetermined and controversial. The expression of CD20 by myeloma cells is heterogeneous, and can be detected only in 13-22% of patients. However, there is increasing interest in testing anti-CD20 therapy in myeloma because of recent studies suggesting the existence of clonogenic CD20-positive precursor B cells in the disease. This article reviews the rationale, preclinical and clinical activity of anti-CD20 therapy in myeloma. Clinical trials show that anti-CD20 therapy with rituximab elicits a partial response in approximately 10% of CD20+ patients with multiple myeloma. In addition, there is preliminary evidence of disease stabilization in 50-57% of CD20+ patients for a period of 10-27 months. Further large-scale clinical trials are therefore needed to establish the role of this promising strategy in the treatment of myeloma.

Original languageEnglish (US)
Pages (from-to)135-148
Number of pages14
JournalBritish Journal of Haematology
Volume141
Issue number2
DOIs
StatePublished - Apr 2008

Fingerprint

Multiple Myeloma
Monoclonal Antibodies
B-Lymphocytes
Clinical Trials
Therapeutics
B-Lymphoid Precursor Cells
Lymphoproliferative Disorders

Keywords

  • CD20 plasma cells
  • I-131 tositumomab
  • Immunotherapy
  • Rituximab
  • Y-90 ibritumomab

ASJC Scopus subject areas

  • Hematology

Cite this

Anti-CD20 monoclonal antibody therapy in multiple myeloma. / Kapoor, Prashant; Greipp, Patricia T; Morice, William G.; Rajkumar, S Vincent; Witzig, Thomas Elmer; Greipp, Philip R.

In: British Journal of Haematology, Vol. 141, No. 2, 04.2008, p. 135-148.

Research output: Contribution to journalArticle

@article{f48841ece96247c6be1255380255066b,
title = "Anti-CD20 monoclonal antibody therapy in multiple myeloma",
abstract = "CD20 is a particularly appealing target that is expressed on the surface of almost all B cells, with no significant shedding, secretion or internalization. In contrast to the demonstrated efficacy of anti-CD20 strategies in various B-cell lymphoproliferative disorders, the role of such therapy in multiple myeloma is undetermined and controversial. The expression of CD20 by myeloma cells is heterogeneous, and can be detected only in 13-22{\%} of patients. However, there is increasing interest in testing anti-CD20 therapy in myeloma because of recent studies suggesting the existence of clonogenic CD20-positive precursor B cells in the disease. This article reviews the rationale, preclinical and clinical activity of anti-CD20 therapy in myeloma. Clinical trials show that anti-CD20 therapy with rituximab elicits a partial response in approximately 10{\%} of CD20+ patients with multiple myeloma. In addition, there is preliminary evidence of disease stabilization in 50-57{\%} of CD20+ patients for a period of 10-27 months. Further large-scale clinical trials are therefore needed to establish the role of this promising strategy in the treatment of myeloma.",
keywords = "CD20 plasma cells, I-131 tositumomab, Immunotherapy, Rituximab, Y-90 ibritumomab",
author = "Prashant Kapoor and Greipp, {Patricia T} and Morice, {William G.} and Rajkumar, {S Vincent} and Witzig, {Thomas Elmer} and Greipp, {Philip R.}",
year = "2008",
month = "4",
doi = "10.1111/j.1365-2141.2008.07024.x",
language = "English (US)",
volume = "141",
pages = "135--148",
journal = "British Journal of Haematology",
issn = "0007-1048",
publisher = "Wiley-Blackwell",
number = "2",

}

TY - JOUR

T1 - Anti-CD20 monoclonal antibody therapy in multiple myeloma

AU - Kapoor, Prashant

AU - Greipp, Patricia T

AU - Morice, William G.

AU - Rajkumar, S Vincent

AU - Witzig, Thomas Elmer

AU - Greipp, Philip R.

PY - 2008/4

Y1 - 2008/4

N2 - CD20 is a particularly appealing target that is expressed on the surface of almost all B cells, with no significant shedding, secretion or internalization. In contrast to the demonstrated efficacy of anti-CD20 strategies in various B-cell lymphoproliferative disorders, the role of such therapy in multiple myeloma is undetermined and controversial. The expression of CD20 by myeloma cells is heterogeneous, and can be detected only in 13-22% of patients. However, there is increasing interest in testing anti-CD20 therapy in myeloma because of recent studies suggesting the existence of clonogenic CD20-positive precursor B cells in the disease. This article reviews the rationale, preclinical and clinical activity of anti-CD20 therapy in myeloma. Clinical trials show that anti-CD20 therapy with rituximab elicits a partial response in approximately 10% of CD20+ patients with multiple myeloma. In addition, there is preliminary evidence of disease stabilization in 50-57% of CD20+ patients for a period of 10-27 months. Further large-scale clinical trials are therefore needed to establish the role of this promising strategy in the treatment of myeloma.

AB - CD20 is a particularly appealing target that is expressed on the surface of almost all B cells, with no significant shedding, secretion or internalization. In contrast to the demonstrated efficacy of anti-CD20 strategies in various B-cell lymphoproliferative disorders, the role of such therapy in multiple myeloma is undetermined and controversial. The expression of CD20 by myeloma cells is heterogeneous, and can be detected only in 13-22% of patients. However, there is increasing interest in testing anti-CD20 therapy in myeloma because of recent studies suggesting the existence of clonogenic CD20-positive precursor B cells in the disease. This article reviews the rationale, preclinical and clinical activity of anti-CD20 therapy in myeloma. Clinical trials show that anti-CD20 therapy with rituximab elicits a partial response in approximately 10% of CD20+ patients with multiple myeloma. In addition, there is preliminary evidence of disease stabilization in 50-57% of CD20+ patients for a period of 10-27 months. Further large-scale clinical trials are therefore needed to establish the role of this promising strategy in the treatment of myeloma.

KW - CD20 plasma cells

KW - I-131 tositumomab

KW - Immunotherapy

KW - Rituximab

KW - Y-90 ibritumomab

UR - http://www.scopus.com/inward/record.url?scp=40949138516&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=40949138516&partnerID=8YFLogxK

U2 - 10.1111/j.1365-2141.2008.07024.x

DO - 10.1111/j.1365-2141.2008.07024.x

M3 - Article

VL - 141

SP - 135

EP - 148

JO - British Journal of Haematology

JF - British Journal of Haematology

SN - 0007-1048

IS - 2

ER -